RNA - NASDAQ
Atrium Therapeutics, Inc.
$12.17
-1.3%Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live SnapshotAtrium Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Atrium Therapeutics, Inc. Cash Flow Statement
RNA • NASDAQ
| Atrium Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-49.5M | -322.3M | -212.2M | -174M | -118M | -44.4M | -24.7M | -11.2M | |
323K | 2.8M | 2.1M | 1.4M | 639K | 373K | 348K | 383K | |
-142K | 0.0 | 0.0 | 0.0 | 0.0 | 84K | 0.0 | 0.0 | |
7.7M | 51.4M | 38.2M | 27.1M | 17.1M | 4.3M | 406K | 60K | |
712K | -18.2M | -8.3M | -615K | 163K | 139K | 7.1M | 447K | |
-200K | -14.6M | 61.1M | 9.8M | 5.3M | 2.3M | 19.4M | 671K | |
-41.1M | -300.9M | -119.1M | -136.3M | -94.8M | -37.1M | 2.5M | -9.7M | |
INVESTING ACTIVITIES | ||||||||
-1.4M | -7.1M | -4.2M | -2.8M | -3.7M | -1.1M | -235K | -49K | |
(0.0) | (0.0) | (0.0) | (187.1M) | (82.5M) | (0.0) | (0.0) | (0.0) | |
(0.0) | -1.4B | -461M | -355.8M | -85.4M | -6.7M | (0.0) | (0.0) | |
0.0 | 586.4M | 335.2M | 168.7M | 6.6M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -187.1M | -82.5M | 0.0 | 0.0 | 0.0 | |
-1.4M | -854.2M | -130.1M | -190M | -82.5M | -7.8M | -235K | -49K | |
FINANCING ACTIVITIES | ||||||||
0.0 | 1B | 60.5M | 344.8M | 174.7M | 274.1M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.7M | 16.7M | 5M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -106K | (0.0) | |
42.6M | 191.8M | 2.1M | 1.4M | 1.6M | 466K | 65K | 162K | |
42.6M | 1.2B | 93.9M | 346.2M | 176.3M | 272M | 89.2M | 5.1M | |
CASH FLOW SUMMARY | ||||||||
0.0 | 37.3M | -155.3M | 19.9M | -1M | 227.1M | 91.5M | -4.6M | |
0.0 | 185.4M | 340.6M | 320.7M | 321.7M | 94.6M | 3.1M | 7.7M | |
0.0 | 222.7M | 185.4M | 340.6M | 320.7M | 321.7M | 94.6M | 3.1M | |
-42.6M | -307.9M | -123.3M | -139.1M | -98.6M | -38.2M | 2.3M | -9.7M |
SEC Filings
RNA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | February 27, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 14, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 25, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 13, 2025 | 2025 |
Related Guides
Continue your RNA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.